RUNX1 and acute myeloid leukemia: Wei and co-authors [109] reported a CR/CRi rate of 71% (95% in newly diagnosed AML versus 42% in secondary AML) and response rates of 90% for NPM1, RUNX1, and IDH1 mutated patients versus 33% for TP53 mutated patients.